More than 25 publications in peer-reviewed journals and 20 abstracts presented at national scientific conferences (recent selected publications and abstracts listed below):
Cannon LA, Kereiakes DJ, Mann T; Popma JJ, Mooney MR, Mishkel GJ, Lee TC, MD, Wilson BH, Stuckey TD, Orlow S, McGarry T, Ring ME, Kellett MA, Underwood P, Dawkins KD: TAXUS PERSEUS Small Vessel: A Prospective Evaluation in a non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels. EuroIntervention 6: 920-927, 2011. http://www.pcronline.com/eurointervention/34th_issue/161/
Daratha KD, Short RA, Corbett C, Ring ME, Alicic R, Choka R, Tuttle KR, Risks of Hospital Readmission and Death in Patients with Kidney Disease. Clinical Journal of the American Society of Nephrology 7: 409-416, 2012.
Povsic TJ, Vavalle JP, Aberle LG, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE, s Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N, Zelenkofske SL, Becker RC, Alexander JH on behalf of the RADAR Investigators: A Randomized, Partially Blinded, Multicenter, Active-Controlled, Phase 2b, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System in Patients with Acute Coronary Syndromes: Results of the RADAR Phase 2b Trial. Eur Heart Journal; 2012 published on line August 2, 2012.
Waksman R, Ghali M, Goodroe R, Ryan T, Turco M, Ring M, McGarry T, Dobies D, Shammas N, Steinberg D, Swymelar S, Kaneshige K, Torguson R. Percutaneous Coronary Intervention With Second-Generation Paclitaxel-Eluting Stents Versus Everolimus-Eluting Stents in United States Contemporary Practice (REWARDS TLX Trial). Am J Cardiol 110: 1119-1124, 2012. http://www.ajconline.org/article/S0002-9149(12)01520-2/abstract
Ring ME, Daratha KB, Short RA, Dominik DA, Shuler L, Tuttle KR: Two-Year Safety and Revascularization Outcomes Following Coronary Artery Intervention with Bare Metal Stents Versus Strategies of Selective or Predominant Drug Eluting Stents in a Community Setting. Journal of the American College of Cardiology 51 (no. 10 suppl. B): B35, 2008 (Scientific Sessions of the American College of Cardiology, 2008).
Ring ME, Daratha KB, Parrish PR, Dominik DA, Short RA, Tuttle KR: Comparison of Long Term Outcomes After Coronary Stenting in the Bare Metal Stent and Drug Eluting Stent Eras. Am J Cardiol 2009; 104:156-157D (Transcatheter Cardiovascular Therapeutics, 2009).
Kereiakes DJ, Cannon LA, Mooney M, Lee TC, Ring M, Underwood P, Dawkins KD, The PERSEUS Small Vessel Trial of the Novel Thin Strut Platinum-Chromium TAXUS Element Paclitaxel-Eluting Stent (submitted to 2010 ACC Scientific Sessions)
Ring ME, Jin R, Wu Y, Grunkemeier GL: Use of a Bare Metal Stent or Balloon Angioplasty Alone in Contemporary Percutaneous Coronary Interventional Practice is an Independent Predictor of In-Hospital Mortality. Journal of the American College of Cardiology 57 (no. 14 suppl. A): 127, 2011 (Scientific Sessions of the American College of Cardiology, 2011).
Waksman R, Ghali M, Goodroe R, Ryan T, Turco M, Ring M, McGarry T, Dobies D, Shammas N, Steinberg D, Swymelar S, Torguson R: REWARDS TLX: Registry Experience at Washington Heart Center: TAXUS Liberte vs. Xience V. Journal of the American College of Cardiology 57 (no. 14 suppl. A): 120, 2011 (Scientific Sessions of the American College of Cardiology, 2011).
Daratha KB, Ring ME, Himmelfarb J, Tuttle KR: Risk of Mortality and Re-Hospitalization among Patients with Acute Myocardial Infarction and Acute Kidney Injury. J Am Soc Nephrol 23: 119A, 2012 (American Society of Nephrology, Kidney Week; 2012).
The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey.Responses are measured on a 10 - point scale, with 10 being the best score. These scores are then translated to a 5 - point scale in order to display results in a 5 - star rating.Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments.